BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23321509)

  • 21. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
    Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
    Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
    Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
    Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical observation of partial pancreatectomy as part of primary cytoreductive surgery in advanced epithelial ovarian cancer].
    Xiang LB; Tu YX; He TC; Pei X; Shen XX; Yang WT; Wu XH; Yang HJ
    Zhonghua Fu Chan Ke Za Zhi; 2016 May; 51(5):361-5. PubMed ID: 27256444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Pérez-Milán F; Ortiz-Quintana L
    Surg Oncol; 2014 Mar; 23(1):40-4. PubMed ID: 24183480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer.
    Grabowski JP; Harter P; Hils R; Lorenz D; Kaub C; Barinoff J; Heitz F; Traut A; du Bois A
    Gynecol Oncol; 2012 Jul; 126(1):54-7. PubMed ID: 22472462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
    Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T
    Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
    Fan XM; Zhang J; Niu SH; Li KX; Song CZ
    Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
    Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE
    J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer.
    Wright JD; Herzog TJ; Neugut AI; Burke WM; Lu YS; Lewin SN; Hershman DL
    Obstet Gynecol; 2012 Oct; 120(4):871-81. PubMed ID: 22996105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
    Falcone F; Scambia G; Benedetti Panici P; Signorelli M; Cormio G; Giorda G; Bogliolo S; Marinaccio M; Ghezzi F; Rabaiotti E; Breda E; Casella G; Fanfani F; Di Donato V; Leone Roberti Maggiore U; Greggi S
    Gynecol Oncol; 2017 Oct; 147(1):66-72. PubMed ID: 28716306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
    So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
    Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
    Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
    Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
    BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.
    Taşkın S; Güngör M; Ortaç F; Öztuna D
    Arch Gynecol Obstet; 2013 Dec; 288(6):1399-403. PubMed ID: 23775264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
    Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S
    Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anesthetic selection and disease-free survival following optimal primary cytoreductive surgery for stage III epithelial ovarian cancer.
    Elias KM; Kang S; Liu X; Horowitz NS; Berkowitz RS; Frendl G
    Ann Surg Oncol; 2015 Apr; 22(4):1341-8. PubMed ID: 25287437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
    Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
    Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
    Suidan RS; Leitao MM; Zivanovic O; Gardner GJ; Long Roche KC; Sonoda Y; Levine DA; Jewell EL; Brown CL; Abu-Rustum NR; Charlson ME; Chi DS
    Gynecol Oncol; 2015 Aug; 138(2):246-51. PubMed ID: 26037900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.